Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

Journal of Clinical Oncology

Volumn 19, Issue 8, 2001, Pages 2319-2333

  Sausville, E A ^a   Arbuck, S G ^a   Messmann, R ^a   Headlee, D ^a   Bauer, K S ^a   Lush, R M ^a   Murgo, A ^a   Figg, W D ^a   Lahuse, T ^a   Jaken, S ^a   Jing, X X ^a   Roberge, M ^a   Fuse, E ^a   Kuwabara, T ^a   Senderowicz, A M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; DNA; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG RESPONSE; DRUG SALIVA LEVEL; DRUG TOXICITY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOTENSION; MALE; MAXIMUM TOLERATED DOSE; METABOLIC ACIDOSIS; NAUSEA; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHOSPHORYLATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; TISSUE DISTRIBUTION; VOMITING;

EID: 0035871444     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.8.2319     Document Type: Article

References (40)

1. 1001 Protein kinases redux: Towards 2000
2. The crystal and molecular structure of staurosporine, a new alkaloid from a streptomyces strain
3. UCN-01 and UCN-02, new selective inhibitors of protein kinase C: II. Purification, physicochemical properties, structural determination and biological activities
4. Potent and specific inhibitors of protein kinase C of microbial origin
5. Apoptosis in 7-hydroxystaurosporine treated T-lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2
6. Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells
7. Activation of PKCα down-stream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells
8. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells
9. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell cycle distribution of human epidermoid carcinoma, A431 cells
10. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/ Sdil in p53-mutated human epidermoid carcinoma A431 cells
11. Differential effects of UCN-01, staurosporine and CGP 41251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole
12. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53 independent
13. Clinical pharmacology of UCN-01: Initial observation and comparison to preclinical models
14. Antitumor activity of UCN-01, a selective inhibition of protein kinase C, in murine and human tumor models
15. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein
16. A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva
17. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue
18. Redistribution and enhanced protein kinase C-mediated phosphorylation of alpha and gamma-adducin during renal tumor progression
19. Downregulation of cyclin D1 by transcriptional regression in MCF-7 human breast carcinoma cells induced by flavopiridol
20. 2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide
21. The inhibitory effect of staurosporine on insulin action is prevented by okadaic acid: Evidence for an important role of serial threonine phosphorylation in eliciting insulin like effects
22. Staurosporine inhibits phorbol 12-myristate 13-acetate and insulin-stimulated translocation of GLUT1 and GLUT4 glucose transporters in rat adipose cells
23. Induction by staurosporine of nitric oxide synthase expression in vascular smooth muscle cells: Role of NEKB, CRED, and C/EPB/β
24. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: A new generation of anticancer agents for the new century?
25. 2 checkpoint function in cancer cells with disrupted p53
26. 2checkpoint inhibitor
27. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25
28. Cell-cycle-dependent and ATM-independent expression of human Chk1 kinase
29. Role of human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53
30. 2 arrest though a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase
31. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine
32. The Chk1 protein kinase and the Cdc25C regulatory pathway are targets of the anticancer agent UCN-01
33. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1
34. Drug binding to human alpha-1-acid glycoprotein in health and disease
35. Phase I and pharmacokinetic study of CGP 41251, an inhibitor of PKC
36. PKC412: A protein kinase inhibitor with a broad therapeutic potential
37. Updated results of an exploratory phase II study on a protein kinase C inhibition in low grade lymphoproliferative disorders
38. The protein kinase C inhibitor CGP412151 suppresses cytokine release and extracellular signal-related kinase 2 expression in cancer patients
39. Discovery and design of angiogenesis inhibitors that inhibit tyrosine kinase activities associated with VEGF, FGF, and PDGF receptors